
An Alzheimer's darkhorse fails its first big trial, but offers hope for a long-overlooked hypothesis
Three years ago, Cortexyme emerged out of obscurity with some big-name backers and an unorthodox approach to treating Alzheimer’s.
They moved their drug into a pivotal study the next year, offering one of the first major tests for a hypothesis that has fluttered on the outskirts of Alzheimer’s research for decades: that, in many cases, the disease is driven by infectious agents — the havoc they wreak in the brain and the inflammation the body uses to try to fend them off. And that quashing the infection could slow patients’ cognitive decline.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.